Could a Diabetes Drug Be the Answer to Long COVID?
A potential breakthrough in the battle against long COVID is emerging from an unexpected source: a common diabetes medication.
Recent studies and clinical trials have revealed that metformin, a widely used diabetes drug, might be a simple yet powerful tool to combat the long-term effects of COVID-19 when administered early in the infection.
But here's where it gets intriguing:
An editorial commentary in Clinical Infectious Diseases suggests that metformin could be a game-changer in preventing long COVID. The authors argue that both clinical trials and real-world data support the safety and effectiveness of this familiar diabetes medication in reducing the risk of long-term COVID-19 symptoms.
Understanding Long COVID
COVID-19, caused by the SARS-CoV-2 virus, has led to a global health crisis. While many recover within weeks, a significant number of individuals develop long COVID, a condition with lingering symptoms lasting months or even years. These symptoms, such as fatigue, breathlessness, chest pain, and cognitive issues ('brain fog'), can severely impact daily life and functionality.
Diabetes Drug's Surprising Antiviral Role
The use of diabetes medication for viral infections might seem unconventional, but it's not without scientific basis. Metformin, a biguanide, was initially investigated for treating viruses and malaria. Despite concerns about lactic acidosis with similar drugs in the past, metformin has demonstrated antiviral properties in lab studies since the 2000s, making it a promising candidate for COVID-19 treatment.
And this is the part most people miss:
Metformin's potential against COVID-19 was first hinted at by early research, including observational studies and computer modeling. Its low cost, widespread availability, and excellent safety profile make it an attractive option for clinical trials.
Clinical Trials Uncover Promising Results
The COVID-OUT trial, conducted in July 2021, aimed to assess the effectiveness of early metformin treatment in preventing long COVID. The trial found that metformin reduced the risk of long COVID by a remarkable 41% over 10 months. Strikingly, starting treatment within three days of symptom onset led to a 63% reduction, emphasizing the importance of early intervention.
A subsequent randomized trial revealed that metformin significantly reduced the viral load in COVID-19 patients compared to a placebo. This finding suggests a potential biological mechanism for its effectiveness in reducing long COVID risk.
To ensure these results were not isolated, researchers conducted ACTIV-6, a larger randomized trial. This study included participants with normal BMI and those with prior COVID-19 infections, demonstrating metformin's safety and effectiveness across a broader patient spectrum.
Conclusions and Implications
The COVID-OUT and ACTIV-6 trials, both well-designed and large-scale, indicate that metformin can reduce the risk of long COVID by approximately 40-50%. These findings are further supported by real-world healthcare data analyses. While long COVID was a secondary outcome in these trials, the consistent results across diverse populations and analytical methods bolster confidence in metformin's potential.
Given its safety, efficacy, and accessibility, the authors propose that metformin should be offered to outpatients with acute COVID-19 as a preventive measure. This strategy could significantly lessen the burden of long COVID on individuals and healthcare systems alike.
The question remains: Will metformin become a standard part of COVID-19 treatment protocols?
Journal Reference:
Bramante, C. T., & Boulware, D. R. (2026). Preventing Long COVID With Metformin. Clinical Infectious Diseases. DOI: https://doi.org/10.1093/cid/ciaf700. https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaf700/8444410
